Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$0.36 USD

0.36
5,668,152

-0.01 (-3.64%)

Updated Nov 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Kevin Cook headshot

Why Sarepta (SRPT) Jumped and We Sold

Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

    Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

    Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

      Kevin Cook headshot

      Healthcare Heroes That Aren't Done Yet

      Key growth stocks across medical industries tell you the megatrends are in full force for years to come

        Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

        Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

          Kevin Cook headshot

          Recession is Coming! Not

          Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk

            Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

            Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.

              Bluebird Up on Buyout Speculation After Celgene/Juno Deal

              Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.

                Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

                Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.

                  bluebird bio (BLUE) Soars: Stock Adds 7.3% in Session

                  bluebird bio (BLUE) was a big mover last session, as the company saw its shares rise more than 7% on the day.

                    Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

                    There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

                      Celgene Provides 2017 Preliminary Results & 2018 View

                      Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.

                        4 Biotech Stocks That More Than Doubled This Year

                        We take a look at a few biotech stocks whose price has increased more than 100% in 2017.

                          CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

                          The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.

                            Company News For Dec 12, 2017

                            Companies in the news are: KMG,ARGX,BPMC,BLUE

                              Bluebird's Shares Jump on Strong Data for CAR-T Therapy

                              bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.

                                Novartis Reports Updated Results from Kymriah's JULIET Study

                                Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.

                                  Ryan McQueeney headshot

                                  Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today

                                  Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.

                                    Gilead Sciences to Acquire Cell Design Labs for $567 Million

                                    Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.

                                      Celgene CAR-T Therapy Gets Breakthrough Therapy Designation

                                      FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.

                                        Why Earnings Season Could Be Great for bluebird bio (BLUE)

                                        bluebird bio (BLUE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                                          Sweta Killa headshot

                                          5 Top Performing Stocks of the Top ETF of August

                                          Inside the top performing ETF of August and its top stocks.

                                            bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session

                                            bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

                                              Ryan McQueeney headshot

                                              Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap

                                              The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.

                                                Kevin Cook headshot

                                                Indecision Won't Kill You, But It Will Take Your Money

                                                The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.

                                                  Ryan McQueeney headshot

                                                  Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition

                                                  Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).